Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
Clearmind Medicine (Nasdaq: CMND) announced that CEO Dr. Adi Zuloff-Shani will be a featured speaker at the “Women in Psychedelic Leadership: Driving Innovation & Governance” webinar on October 29, 2025 at 9:00 AM PT / noon ET.
Dr. Zuloff-Shani will discuss psychedelic research, governance, and therapeutic development—highlighting work on alcohol use disorder, cocaine addiction, and obesity—and share perspectives from her 20+ years in biomedical R&D. The webinar is hosted by the Psychedelic Association of Canada and available via Eventbrite; Clearmind invites investors, researchers, and stakeholders to register and learn about the company’s strategic direction in psychedelic medicine.
Clearmind Medicine (Nasdaq: CMND) ha annunciato che la CEO Dott.ssa Adi Zuloff-Shani sarà relatrice al webinar “Women in Psychedelic Leadership: Driving Innovation & Governance” in programma il 29 ottobre 2025 alle 9:00 PT / 12:00 ET.
La Dott.ssa Zuloff-Shani parlerà di ricerca psichedelica, governance e sviluppo terapeutico, mettendo in evidenza il lavoro su disturbo da uso di alcol, dipendenza da cocaina e obesità, e condividerà le prospettive derivate da oltre 20 anni di attività in R&D biomedica. Il webinar è organizzato dall’Associazione Psichedelica del Canada ed è disponibile su Eventbrite; Clearmind invita investitori, ricercatori e stakeholder a registrarsi e a conoscere l’indirizzo strategico dell’azienda nel campo della medicina psichedelica.
Clearmind Medicine (Nasdaq: CMND) anunció que la directora ejecutiva Dr. Adi Zuloff-Shani será ponente destacada en el seminario web “Women in Psychedelic Leadership: Driving Innovation & Governance” el 29 de octubre de 2025 a las 9:00 AM PT / 12:00 PM ET.
La Dra. Zuloff-Shani discutirá investigaciones psicodélicas, gobernanza y desarrollo terapéutico, destacando trabajos sobre trastorno por uso de alcohol, adicción a la cocaína y obesidad, y compartirá perspectivas de sus más de 20 años en I+D biomédica. El seminario web es organizado por la Asociación de Psicodélicos de Canadá y está disponible vía Eventbrite; Clearmind invita a inversores, investigadores y partes interesadas a registrarse y conocer la dirección estratégica de la empresa en la medicina psicodélica.
Clearmind Medicine (Nasdaq: CMND)는 CEO Dr. Adi Zuloff-Shani가 “Women in Psychedelic Leadership: Driving Innovation & Governance” 웨비나의 기조 연설자로 참여하게 되었다고 발표했습니다. 일시: 2025년 10월 29일 오전 9시 PT / 오후 12시 ET.
줄로프-샤니 박사는 사이키델릭 연구, 거버넌스 및 치료 개발에 대해 논의할 것이며 알코올 사용 장애, 코카인 중독, 비만 등에 대한 연구를 강조하고, 생물의학 R&D에서 20년이 넘는 경험에서 얻은 관점을 공유할 것입니다. 이 웨비나는 캐나다 사이키델릭 협회가 주최하며 Eventbrite를 통해 이용 가능합니다. Clearmind은 투자자, 연구자 및 이해관계자들에게 등록하고 사이키델릭 의학에 대한 회사의 전략적 방향을 알아볼 것을 권장합니다.
Clearmind Medicine (Nasdaq: CMND) a annoncé que la PDG Dr. Adi Zuloff-Shani sera intervenante lors du webinaire « Women in Psychedelic Leadership: Driving Innovation & Governance » le 29 octobre 2025 à 9h00 PT / 12h ET.
La Dre Zuloff-Shani abordera la recherche psychédéliste, la gouvernance et le développement thérapeutique — en mettant en lumière des travaux sur les troubles lié à l’usage d’alcool, la dépendance à la cocaïne et l’obésité — et partagera des perspectives issues de ses plus de 20 années dans la R&D biomédicale. Le webinaire est organisé par l’Association Psychedelica du Canada et est disponible via Eventbrite; Clearmind invite les investisseurs, chercheurs et parties prenantes à s’inscrire et à découvrir l’orientation stratégique de l’entreprise dans le domaine de la médecine psychédélique.
Clearmind Medicine (Nasdaq: CMND) gab bekannt, dass CEO Dr. Adi Zuloff-Shani eine Hauptrednerin bei dem Webinar „Women in Psychedelic Leadership: Driving Innovation & Governance“ sein wird, am 29. Oktober 2025 um 9:00 Uhr PT / 12:00 Uhr ET.
Dr. Zuloff-Shani wird über psychedelische Forschung, Governance und therapeutische Entwicklung sprechen — und Arbeiten zu Alkoholgebrauchsstörung, Kokainabhängigkeit und Fettleibigkeit hervorheben — sowie Perspektiven aus über 20 Jahren Biomedizin-Forschungs- und Entwicklungsarbeit teilen. Das Webinar wird von der Psychedelic Association of Canada ausgerichtet und ist über Eventbrite verfügbar; Clearmind lädt Investoren, Forscher und Stakeholder ein, sich zu registrieren und sich über die strategische Ausrichtung des Unternehmens im Bereich der psychedelischen Medizin zu informieren.
Clearmind Medicine (Nasdaq: CMND) أعلنت أن المديرة التنفيذية الدكتورة آدي زولوڤ-شاني ستشارك كمتحدثة رئيسية في الندوة عبر الويب بعنوان «النساء في قياديّة المواد النفسية: قيادة الابتكار والحوكمة» في 29 أكتوبر 2025 الساعة 9:00 صباحًا بتوقيت المحيط الهادئ / الظهر بتوقيت شرق الولايات المتحدة.
ستناقش الدكتورة زولوڤ-شاني أبحاث المواد النفسية والحوكمة وتطوير العلاج، مع تسليط الضوء على أعمالها في اضطراب استخدام الكحول، والإدمان على الكوكايين، والسمنة، وستشارك وجهات نظر من أكثر من 20 عامًا في البحث والتطوير الحيوي. الندوة عبر الويب منظّمة من قبل جمعية المواد النفسية في كندا ومتاحة عبر Eventbrite؛ تدعو Clearmind المستثمرين والباحثين وأصحاب المصلحة إلى التسجيل ومعرفة الاتجاه الاستراتيجي للشركة في دواء النفساني.
Clearmind Medicine (Nasdaq: CMND) 宣布，首席执行官 Adi Zuloff-Shani 博士 将成为“Women in Psychedelic Leadership: Driving Innovation & Governance”网络研讨会的特邀发言人，时间为2025年10月29日太平洋时间上午9:00 / 东部时间中午。
Zuloff-Shani 博士将讨论迷幻药研究、治理和治疗开发——重点介绍在酒精使用障碍、可卡因成瘾和肥胖方面的工作——并分享她在生物医学研发领域超过20年的经验。该网络研讨会由加拿大迷幻药协会主办，通过 Eventbrite 提供；Clearmind 邀请投资者、研究人员和利益相关者注册，并了解公司在迷幻药物领域的战略方向。
- None.
- None.
Vancouver, Canada, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, is proud to announce that its CEO, Dr. Adi Zuloff-Shani, will participate as a featured speaker at the upcoming “Women in Psychedelic Leadership: Driving Innovation & Governance” webinar. The event, hosted by the Psychedelic Association of Canada, is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online via Eventbrite.
Dr. Zuloff-Shani, a biomedical research and development executive with over 20 years of experience in the healthcare industry, brings a wealth of knowledge in therapeutics development within heavily regulated environments. Her participation underscores Clearmind’s commitment to advancing psychedelic medicine, particularly in areas such as alcohol use disorder, cocaine addiction, and obesity, through rigorous scientific innovation and ethical leadership. The webinar will explore how women are shaping the future of psychedelic research, governance, and healing, with Dr. Zuloff-Shani sharing insights from her extensive background, including her Ph.D. in human biology and immunology from Bar-Ilan University.
Clearmind invites investors, researchers, and stakeholders to join the webinar to gain valuable insights into the company’s strategic direction and the broader psychedelic landscape. Registration is available at https://www.eventbrite.ca/e/women-in-psychedelic-leadership-tickets-1736078029119. For more information on Clearmind’s upcoming events and initiatives, visit https://www.clearmindmedicine.com/.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
When is Clearmind (CMND) CEO Dr. Adi Zuloff-Shani speaking at the Women in Psychedelic Leadership webinar?
How can investors register to attend the Clearmind (CMND) webinar presentation on October 29, 2025?
What topics will Clearmind (CMND) CEO cover during the Women in Psychedelic Leadership webinar?
Will the Women in Psychedelic Leadership webinar featuring Clearmind (CMND) be available online?
Where can I find more information about Clearmind (CMND) events and initiatives after the webinar?
